BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Mesoblast Limited 

Level 1, 843A Glenhuntly Road

Caulfield South  VIC  3162  Australia
Phone: 03-9618-7000 Fax:


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Celgene (CELG), Mesoblast (MSB.AX) $45M Deal "Speaks Volumes" About Big Pharma's Cell Therapy Plans, Says Pluristem Therapeutics (PSTI) 4/14/2015 6:27:36 AM
Mesoblast (MSB.AX) Hits Highest Point in a Decade, as Celgene (CELG) Bets $45 Million 4/13/2015 6:00:42 AM
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015 7:14:13 AM
Mesoblast Limited (MSB.AX) Key Patent Allowed In Japan For The Treatment Of Heart Diseases, Stroke, And Other Vascular Conditions 3/27/2015 6:11:36 AM
Mesoblast Limited (MSB.AX) Selected For Fast Track Access To Potential Investment Incentives In Japan 3/19/2015 7:41:05 AM
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015 8:51:42 AM
Mesoblast Limited (MSB.AX) Reports 2015 Half-Year Results 2/12/2015 7:43:42 AM
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015 6:58:54 AM
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014 7:28:59 AM
Mesoblast Limited (MSB.AX) Partner JCR Pharmaceuticals Files For Marketing Approval Of The First Allogeneic Stem Cell Product In Japan 10/1/2014 7:51:20 AM
12345678910...